Stockreport

Arbutus up 3% after hours on encouraging data on HBV candidate AB-506 [Seeking Alpha]

Arbutus Biopharma Corporation  (ABUS) 
Last arbutus biopharma corporation earnings: 11/6 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.arbutusbio.com/node/5806
PDF Arbutus Biopharma (NASDAQ: ABUS ) perks up   after hours in reaction to positive data from a Phase 1a/1b clinical trial evaluating HBV capsid inhibitor AB-506 [Read more]